x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

The Readout Loud

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

business

All Episodes

23:02

Episode 22: Biotech's battle for talent, Sanofi's...

The Readout Loud ·

2018/08/02

What juicy perks do biotech startups offer to lure increasingly hard-to-find talent? How does Sanofi plan to make up for lost time in the lucrative field of oncology? And veteran biotech journalist Luke Timmerman talks about what it's like to climb Mt. Everest.

en

24:58

Episode 21 - A debatable Alzheimer's breakthrough,...

The Readout Loud ·

2018/07/26

What qualifies as "robust" when it comes to data? Is digital health a bubble? And can Gilead Sciences survive without men named John?

en

25:30

Episode 20 - CRISPR freakouts, drug prices meet...

The Readout Loud ·

2018/07/19

Can drug prices swing an election? Is every quarter a “great quarter“? And why is everyone freaking out about CRISPR? Listen, and all will be explained.

en

24:46

Episode 19: Trump's telephonic prowess, Biogen's...

The Readout Loud ·

2018/07/12

Can phone calls bring down drug prices? Do mom-and-pop investors have a prayer against hedge funds? And how do you know whether an Alzheimer's drug actually works?

en

19:49

Episode 18: Biotech's six-month review, how to become...

The Readout Loud ·

2018/07/05

Adam and Damian recap the past six months in biotech. Investor and philanthropist, Sheff Station, stops by and gives tips on how to become a day trader, and analysts questioning their very existence.

en

23:11

Episode 17: A friendly FDA, biosimilar awkwardness...

The Readout Loud ·

2018/06/28

How did the FDA become so friendly to the drug industry? The thorny issue of using 23andMe to unite families separated at the border, and Rebecca explains how drugs are priced in China.

en

25:45

Episode 16: Sarepta's big week, Theranos' legal woes...

The Readout Loud ·

2018/06/21

Is Sarepta Therapeutics worth $10 billion? Will Theranos' Elizabeth Holmes go behind bars? And how does AI fit into biotech?

en

23:45

Episode 15: Problematic parties, Nitpicking NASH, and...

The Readout Loud ·

2018/06/14

The problem with the topless dancers at PABNAB. Are investors overestimating the market for fatty liver drugs? And how many lives do biotech entrepreneurs get?

en

26:56

Episode 14: Twitter vitriol, biotech jargon, and the...

The Readout Loud ·

2018/06/07

Why is Twitter so mean to Axovant? Adam teaches a crash course on biostatistics. And will sci-fi gene and cell therapies ever go mainstream.

en

22:31

Episode 13: Spending millions on fatty liver disease....

The Readout Loud ·

2018/05/31

Is the drug industry spending millions on a made-up disease? Have the latest cancer drugs been overhyped? And why does anyone go to BIO?

en

27:48

Episode 12: Ebola should worry you, again; 23andMe's...

The Readout Loud ·

2018/05/24

How worried should you be about Ebola? Can the government lower drug prices without hurting the drug industry? And is socceromics a thing? Listen this week to find out.

en

22:45

Episode 11: Inside the Theranos collapse, Valeant's...

The Readout Loud ·

2018/05/17

What do you call a unicorn without a horn? Is your colleague wearing a wire? And is Jentadueto a drug name or a complicated espresso drink?

en

22:28

Episode #10: Cohen, Trump, Novartis, oh my; Spark +...

The Readout Loud ·

2018/05/10

On today's show, we dig into the no good, very bad day Novartis had when the world got wind of its ties to President Trump's personal attorney, a discussion of how the world's biggest cancer conference used to be the Wild West for investors, and an exploration of one health system's plan to bring genomics to the masses. Also STAT's Eric Boodman joins us to talk about how a pricey new gene therapy has created a fascinating situation in Amish country.

en

27:37

Episode #9 - Bill Gates on deadly flu, Chinese...

The Readout Loud ·

2018/05/03

We talk to Bill Gates about the flu that could kill millions. Is China too enamored with biotech startups? And how do you find a cold case killer? Genetics.

en

25:04

Episode #8 - Megamergers, migraines, and biotech's...

The Readout Loud ·

2018/04/26

What's a good use of $64 billion? Is Big Biotech boring now? And what's the best way to sell hair restoration products to men?

en

21:55

Episode #7 - Coke and Pepsi of lung cancer, a...

The Readout Loud ·

2018/04/19

Is Bristol-Myers Squibb into self-sabotage? Is Congress coming for Gut Guy? And why does Goldman Sachs love money so much?

en

23:33

Episode #6 - Biotech buyouts, CEO breakups, and The...

The Readout Loud ·

2018/04/12

Why are biotech investors suddenly so exuberant? What does it mean when a CEO scrubs his LinkedIn profile? And can CRISPR turn your dog into a winged hellhound bent on destroying Chicago?

en

22:32

Episode #5 - The FDA's cold shoulder, the latest...

The Readout Loud ·

2018/04/05

What's it like to be a biotech investor? Do you know where your genetic data are? And what does it mean when the FDA swipes left on your drug?

en

23:36

Episode #4 - Mr. Drug CEO doesn't go to DC,...

The Readout Loud ·

2018/03/29

Why aren't pharma CEOs getting hauled into Congress? Which biotech companies got a failing grade this quarter? And why is there no Kelley Blue Book for the price tag of a medicine?

en

24:46

Episode #3 - A gene therapy story, breaking down...

The Readout Loud ·

2018/03/22

What’s it like to watch gene therapy happen? Is the next big cancer clinical trial going to work? And is “right to try” going to defang the FDA?

en

383 results

Similar Podcasts

TaxTalent.com The Golden Rule Podcast

Adam Golden

TaxTalent.com Podcast

Tony Santiago

Handelsblatt Crime - spannende Streitfälle der deutschen Wirtschaft

Ina Karabasz, Solveig Gode, Sönke Iwersen

Deffner und Zschäpitz – Der Wirtschafts-Talk von WELT

WELT

Black Box - La scatola nera della finanza

Guido Brera e Gian Luca Comandini -...